title: Imatinib mesylate (gleevec) hepatotoxicity.
authors.affiliation: Center for Liver Diseases, Division of Hepatology, University of Miami Leonard M Miller School of Medicine, Miami, FL 33136, USA.
authors.forename: Ayse L
authors.initials: AL
authors.lastname: Mindikoglu
authors.forename: Arie
authors.initials: A
authors.lastname: Regev
authors.forename: Pablo A
authors.initials: PA
authors.lastname: Bejarano
authors.forename: Enrique J
authors.initials: EJ
authors.lastname: Martinez
authors.forename: Lennox J
authors.initials: LJ
authors.lastname: Jeffers
authors.forename: Eugene R
authors.initials: ER
authors.lastname: Schiff
mesh_terms: D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001219:Aspartate Aminotransferases / Q000097:blood; D001549:Benzamides; D001663:Bilirubin / Q000097:blood; D001772:Blood Cell Count; D004909:Erythrocyte Indices; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D017093:Liver Failure / Q000097:blood / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D009336:Necrosis; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011517:Prothrombin Time; D011743:Pyrimidines / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D001663:Bilirubin